• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PANITUMUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • PANITUMUMAB chembl:CHEMBL1201827 ApprovedAntineoplastic

    Alternate Names:

    PANITUMUMAB
    E7.6.3
    L01XC08
    ABX-EGF
    VECTIBIX
    chemidplus:339177-26-3
    drugbank:01269
    chembl:CHEMBL1201827
    rxcui:263034

    Drug Info:

    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    Year of Approval 2006
    Drug Class antineoplastic agents
    FDA Approval Colorectal cancer (KRAS wild type)
    Drug Class Therapeutic Antibodies
    (11 More Sources)

    Publications:

    Montagut et al., 2012, Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer., Nat. Med.
    Lynch et al., 2002, Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment., Semin. Oncol.
    Heymach et al., 2006, Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer., Clin. Cancer Res.
    Yang et al., 2001, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy., Crit. Rev. Oncol. Hematol.
    Keating, 2010, Panitumumab: a review of its use in metastatic colorectal cancer., Drugs
    Wu et al., 2008, Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer., Clin Ther
    Jean et al., 2008, Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer., Pharmacotherapy
    Foon et al., 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody., Int. J. Radiat. Oncol. Biol. Phys.
    Saadeh et al., 2007, Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer., Ann Pharmacother
    Keating, 2010, Spotlight on panitumumab in metastatic colorectal cancer., BioDrugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Segaert et al., 2005, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors., Ann. Oncol.
    Cohen, 2003, Epidermal growth factor receptor as a therapeutic target in colorectal cancer., Clin Colorectal Cancer
    Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J
    Rossi A et al., 2013, Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?, Cancer Treat Rev
    Mayo C et al., 2012, Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications., Pharmacogenomics
    Van Cutsem et al., 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer., N. Engl. J. Med.
    Vermorken JB et al., 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer., N Engl J Med
    Funke S et al., 2008, Pharmacogenetics in colorectal cancer: a systematic review., Pharmacogenomics
    Giusti RM et al., 2008, U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens., Clin Cancer Res
    Jonker et al., 2007, Cetuximab for the treatment of colorectal cancer., N. Engl. J. Med.
    Bonner JA et al., 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck., N Engl J Med
    Normanno N et al., 2006, Epidermal growth factor receptor (EGFR) signaling in cancer., Gene
    Thatcher N et al., 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)., Lancet
    Herbst RS et al., 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2., J Clin Oncol
    Giaccone G et al., 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1., J Clin Oncol
    Jorissen RN et al., 2003, Epidermal growth factor receptor: mechanisms of activation and signalling., Exp Cell Res
    Oddo et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res.
    Sartore-Bianchi et al., 2007, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab., J. Clin. Oncol.
    Arena et al., 2016, MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations., Sci Transl Med
    Sánchez-Martín et al., 2016, The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer., Clin. Cancer Res.
    Shen et al., 2014, EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis., Chin. J. Cancer Res.
    Uchibori et al., 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer., Nat Commun
    Strickler JH et al., 2018, Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer., Cancer Discov
    Seligmann et al., 2016, Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer., JAMA Oncol
    Peeters et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin. Cancer Res.
    De Roock et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol.
    De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Ahronian et al., 2015, Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations., Cancer Discov
    Corcoran RB et al., 2018, Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer., Cancer Discov
    Silkin SV et al., 2016, Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan., J Gastrointest Cancer
    Di Nicolantonio et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J. Clin. Oncol.
    Nicolaides et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin. Cancer Res.
    Hoftijzer et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur. J. Endocrinol.
    Rad et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell
    Maldonado et al., 2003, Determinants of BRAF mutations in primary melanomas., J. Natl. Cancer Inst.
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
    Villanueva et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell
    Tiacci et al., 2011, BRAF mutations in hairy-cell leukemia., N. Engl. J. Med.
    Sosman et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N. Engl. J. Med.
    Brose et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res.
    Gupta-Abramson et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J. Clin. Oncol.
    Ho et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N. Engl. J. Med.
    Rizzo et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat. Rev.
    Lovly et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS ONE
    Falchook et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget
    Mao et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin. Cancer Res.
    Chen et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS ONE
    Nakayama et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br. J. Cancer
    Huillard et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc. Natl. Acad. Sci. U.S.A.
    Nagore et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J. Am. Acad. Dermatol.
    Pratilas et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res.
    McArthur et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol.
    Mao et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol. Biol. Rep.
    De Roock et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther
    Haldar et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev
    Penna et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget
    Corcoran et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov
    Xing et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J. Clin. Oncol.
    Tejpar et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist
    Faber et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov
    Agaimy et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J. Clin. Pathol.
    Kloos et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J. Clin. Oncol.
    Ponti et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol
    Paraiso et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin. Cancer Res.
    Kirkwood et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin. Cancer Res.
    Cardarella et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin. Cancer Res.
    Nissan et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res.
    Greger et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol. Cancer Ther.
    Flaherty et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N. Engl. J. Med.
    Jalili et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J. Natl. Cancer Inst.
    Gandhi et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS ONE
    Rudin et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol
    Hauschild et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet
    Prahallad et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature
    Boulalas et al., Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int. J. Biol. Markers
    Sarker et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin. Cancer Res.
    Crescenzi et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm. Metab. Res.
    Andrulis et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov
    Rubinstein et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med
    Kim et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid
    Dienstmann et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem
    Chapman et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N. Engl. J. Med.
    Tol et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur. J. Cancer
    Ji et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin. Cancer Res.
    Morris et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov
    Sen et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med
    Patel et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer
    He et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett
    Menzies et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin. Cancer Res.
    Lam et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J. Clin. Oncol.
    Zecchin et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol. Cancer Ther.
    Hayes et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin. Cancer Res.
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Meckbach et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS ONE
    Ascierto et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J. Clin. Oncol.
    Walczyk et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin. Endocrinol. (Oxf)
    Howell et al., 2011, Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer., Ann. Surg. Oncol.
    Wan et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell
    Flaherty et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N. Engl. J. Med.
    Coffee et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin. Cancer Res.
    Kurman et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum. Pathol.
    Falchook et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol.
    Hatzivassiliou et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Rowland et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br. J. Cancer
    Flaherty et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N. Engl. J. Med.
    Ohashi et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc. Natl. Acad. Sci. U.S.A.
    Falchook et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet
    Paik et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J. Clin. Oncol.
    Naoki et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res.
    Gautschi et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol
    Davies et al., 2002, Mutations of the BRAF gene in human cancer., Nature
    2016, Triple Therapy Improves Colorectal Cancer Response., Cancer Discov
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Yaeger et al., 2015, Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients., Clin. Cancer Res.
    Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res
    De Roock et al., 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab., JAMA
    Janssen et al., 1987, RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes., Proc. Natl. Acad. Sci. U.S.A.
    Lee et al., 2011, Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations., J. Natl. Cancer Inst.
    Neumann et al., 2009, Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer., Pathol. Res. Pract.
    Amado et al., 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer., J. Clin. Oncol.
    Tyner et al., 2009, High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients., Blood
    Peeters et al., 2013, Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab., J. Clin. Oncol.
    Rowland et al., 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours., Eur. J. Cancer
    Tejpar et al., 2012, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab., J. Clin. Oncol.
    Bokemeyer et al., 2009, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer., J. Clin. Oncol.
    Lièvre et al., 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer., Cancer Res.
    Bokemeyer et al., 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study., Ann. Oncol.
    Schubbert et al., 2007, Hyperactive Ras in developmental disorders and cancer., Nat. Rev. Cancer
    Schirripa et al., 2015, Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer., Ann. Oncol.
    Peeters et al., 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer., J. Clin. Oncol.
    Riely et al., 2008, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma., Clin. Cancer Res.
    Bacher et al., 2006, Implications of NRAS mutations in AML: a study of 2502 patients., Blood
    Migliardi et al., 2012, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas., Clin. Cancer Res.
    Rothenberg et al., 2005, Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma., J. Clin. Oncol.
    Osumi et al., 2015, Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival., Mol Clin Oncol
    Sano et al., 2012, RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group., Int. J. Hematol.
    Kumar et al., 2014, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model., Gastrointest Cancer Res
    Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
    Vogelstein et al., 1990, RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study., Genes Chromosomes Cancer
    Lou et al., 2017, Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab., J Natl Compr Canc Netw
    Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer
    Poulin-Costello et al., 2013, An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer., Target Oncol
    Van Cutsem et al., 2014, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer., Clin. Cancer Res.
    Ramos et al., 2008, Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer., Clin Colorectal Cancer
    Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
    Benson et al., 2017, Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw
    Sartore-Bianchi et al., 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies., Cancer Res.
    Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
    Allegra CJ et al., 2016, Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015., J Clin Oncol
    Sclafani F et al., 2015, Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial., Ann Oncol
    Ying HQ et al., 2014, The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis., Onco Targets Ther
    Saridaki Z et al., 2014, A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy., Clin Cancer Res
    Sha D et al., 2014, Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial)., Clin Cancer Res
    Sebio A et al., 2013, The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients., Pharmacogenet Genomics
    Chen J et al., 2013, Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis., Cancer Chemother Pharmacol
    Bando H et al., 2012, Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan., Jpn J Clin Oncol
    Gajate P et al., 2012, Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab., Clin Colorectal Cancer
    Valtorta E et al., 2013, KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy., Int J Cancer
    Russo et al., 2016, Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer., Cancer Discov
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Douillard et al., 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer., N. Engl. J. Med.
    Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov
    Kasper et al., 2013, Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade., Oncogene
    Vermorken et al., 2013, Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial., Lancet Oncol.
    Kavuri et al., 2015, HER2 activating mutations are targets for colorectal cancer treatment., Cancer Discov
  • PANITUMUMAB   EREG

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26867820


    Sources:
    CIViC PharmGKB

  • PANITUMUMAB   BRAF

    Interaction Score: 2.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Panitumumab + Dabrafenib + Trametinib
    combination therapy Vemurafenib + Panitumumab
    Clinical Status late trials

    PMIDs:
    23325582 21163703 20619739 28783719 25673644 29431699 26687137 19001320 22038996 19773371 23845441 14679157 22180495 21156289 21663470 22356324 12460918 18541894 23406027 21129611 22536370 23470635 23251002 24594804 19018267 22586120 24388723 19010912 24508103 20857202 19537845 21975775 26678033 22448344 25024077 20350999 24163374 19561230 19255327 23031422 22351686 22048237 23833300 24576830 22389471 23020132 22997239 19238210 23524406 22735384 22281684 19404918 25370471 24570209 23612012 20630094 23489023 21426297 21639808 20413299 23812671 23614898 22649091 22972589 24396464 24583796 20368568 24107445 22241789 26619011 24586605 23918947 24354346 21594703 15035987 22663011 23549875 21683865 22805292 23934108 25157968 25989278 20818844 22773810 22608338 21483012 12460919 22743296 12068308 27770002 27312529 28514312 25589621 31515458


    Sources:
    JAX-CKB DoCM CIViC OncoKB

  • PANITUMUMAB   AREG

    Interaction Score: 2.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26867820 23959273


    Sources:
    CIViC PharmGKB

  • PANITUMUMAB   BTC

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   NRG2

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   TGFA

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   KRAS

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status FDA-rejected

    PMIDs:
    20978259 3122217 21398618 19679400 18316791 19075190 23182985 21975775 26812186 19018267 23406027 22734028 19114683 16618717 25157968 21228335 17384584 19255327 26371285 20921462 18794081 16434492 19773371 22392911 16361624 26623049 22407852 24558511 20921465 12460918 2278970 28404754 26540314 23625191 24919569 19064407 26341920 28275037 19223544 27897268 26438111 26162609 25210463 25183481 24727325 23324806 23090619 23071293 22537608 23404247 26644315


    Sources:
    ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB

  • PANITUMUMAB   EGF

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   HBEGF

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   NRG3

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   EGFR

    Interaction Score: 0.81

    Interaction Types & Directionality:
    suppressor (inhibitory)
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    22270724 11894013 16857825 11255078 20481659 18343240 18503402 14967460 17355997 20623992 11752352 16012181 12620146 23959273 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 27312529 17664472 26843189 26888827 24653627 28287083 29196463


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC PharmGKB TTD FDA

  • PANITUMUMAB   NRAS

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive
    Approval Status Phase III

    PMIDs:
    23325582 20619739 24024839 26438111 28275037 26341920


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • PANITUMUMAB   CDKN2A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23746666


    Sources:
    CIViC

  • PANITUMUMAB   MAP2K1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Panitumumab + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    26644315 31227518


    Sources:
    JAX-CKB CIViC

  • PANITUMUMAB   HRAS

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    22797062


    Sources:
    JAX-CKB

  • PANITUMUMAB   NRG1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PANITUMUMAB   PTEN

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19223544


    Sources:
    ClearityFoundationBiomarkers CIViC

  • PANITUMUMAB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy JNJ 38877605 + Panitumumab
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23729478


    Sources:
    JAX-CKB

  • PANITUMUMAB   PIK3CA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19223544


    Sources:
    CIViC

  • PANITUMUMAB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26243863


    Sources:
    JAX-CKB

  • PANITUMUMAB   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Vemurafenib + Panitumumab
    Indication/Tumor Type colon cancer
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • TEND: PANITUMUMAB

    • Version: 01-August-2011

    Alternate Names:
    PANITUMUMAB Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 2006

    Publications:

  • MyCancerGenome: PANITUMUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    ABX-EGF Development Name
    PANITUMUMAB Generic Name
    VECTIBIX Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Colorectal cancer (KRAS wild type)

    Publications:

  • TdgClinicalTrial: PANITUMUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • DoCM: PANITUMUMAB

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Flaherty et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N. Engl. J. Med.
    Falchook et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.

  • PharmGKB: panitumumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Allegra CJ et al., 2016, Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015., J Clin Oncol
    Rowland et al., 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours., Eur. J. Cancer
    Gajate P et al., 2012, Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab., Clin Colorectal Cancer

  • JAX-CKB: Panitumumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Lou et al., 2017, Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab., J Natl Compr Canc Netw
    Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer

  • CIViC: PANITUMUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Di Nicolantonio et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J. Clin. Oncol.
    Ahronian et al., 2015, Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations., Cancer Discov

  • TALC: PANITUMUMAB

    • Version: 12-May-2016

    Alternate Names:
    PANITUMUMAB Primary Drug Name
    PANITUMUMAB Drug Generic Name
    VECTIBIX Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Panitumumab

    • Version: 2020.06.01

    Alternate Names:
    D0HU9H TTD Drug ID

    Drug Info:

    Publications:

  • TTD: ABX-EGF

    • Version: 2020.06.01

    Alternate Names:
    D0P9RG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201827

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Panitumumab

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: PANITUMUMAB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201827

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Panitumumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21